Myelopathy from Waldenström macroglobulinemia: Improvement after Rituximab therapy

Bernardo Liberato; Adrienne Riethmuller; Raymond L. Comenzo; Eric Lis; Jeffrey J. Raizer

doi:10.1023/A:1023912425610

Myelopathy from Waldenström macroglobulinemia: Improvement after Rituximab therapy

Bernardo Liberato, Adrienne Riethmuller, Raymond L. Comenzo, Eric Lis, Jeffrey J. Raizer^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

Original language	English (US)
Pages (from-to)	207-211
Number of pages	5
Journal	Journal of Neuro-Oncology
Volume	63
Issue number	2
DOIs	https://doi.org/10.1023/A:1023912425610
State	Published - Jun 1 2003

Keywords

Myelopathy
Rituximab
Waldenström macroglobulinemia

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1023912425610

Cite this

@article{112884e2120649498ebb08fd8d0d540a,

title = "Myelopathy from Waldenstr{\"o}m macroglobulinemia: Improvement after Rituximab therapy",

abstract = "Approximately 20% of patients with Waldenstr{\"o}m's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.",

keywords = "Myelopathy, Rituximab, Waldenstr{\"o}m macroglobulinemia",

author = "Bernardo Liberato and Adrienne Riethmuller and Comenzo, {Raymond L.} and Eric Lis and Raizer, {Jeffrey J.}",

year = "2003",

month = jun,

day = "1",

doi = "10.1023/A:1023912425610",

language = "English (US)",

volume = "63",

pages = "207--211",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Myelopathy from Waldenström macroglobulinemia

T2 - Improvement after Rituximab therapy

AU - Liberato, Bernardo

AU - Riethmuller, Adrienne

AU - Comenzo, Raymond L.

AU - Lis, Eric

AU - Raizer, Jeffrey J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

AB - Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

KW - Myelopathy

KW - Rituximab

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=0038378995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038378995&partnerID=8YFLogxK

U2 - 10.1023/A:1023912425610

DO - 10.1023/A:1023912425610

M3 - Article

C2 - 12825826

AN - SCOPUS:0038378995

SN - 0167-594X

VL - 63

SP - 207

EP - 211

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 2

ER -

Myelopathy from Waldenström macroglobulinemia: Improvement after Rituximab therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this